Torii Pharmaceutical Yönetim

Yönetim kriter kontrolleri 1/4

Torii Pharmaceutical CEO'su Goichi Matsuda, Mar2019 tarihinde atandı, in görev süresi 5.67 yıldır. şirketin hisselerinin 0.065% doğrudan sahiptir ve bu hisselerin değeri ¥ 85.05M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.2 yıl ve 0.7 yıldır.

Anahtar bilgiler

Goichi Matsuda

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	5.7yrs
CEO sahipliği	0.06%
Yönetim ortalama görev süresi	3.2yrs
Yönetim Kurulu ortalama görev süresi	less than a year

Son yönetim güncellemeleri

Recent updates

CEO

Goichi Matsuda (57 yo)

5.7yrs

Görev süresi

Mr. Goichi Matsuda serves as President, Chief Executive Officer and Representative Director at Torii Pharmaceutical Co., Ltd. since March 26, 2019. He served as Deputy Head of Pharmaceutical Marketing & Pr...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Goichi Matsuda	President	5.7yrs	Veri yok	0.065% ¥ 85.0m
Yukihiro Takashima	General Manager of Finance & Accounting Department	no data	Veri yok	Veri yok
Atsuyuki Kakee	Managing Executive Officer	9.7yrs	Veri yok	Veri yok
Katsunobu Fujiwara	Managing Executive Officer & Pharmaceutical Sales Group Leader	no data	Veri yok	Veri yok
Nobumasa Kondo	Executive Deputy President & Representative Director	no data	Veri yok	0.015% ¥ 19.2m
Noriaki Nishino	Executive Officer	no data	Veri yok	Veri yok
Koji Matsuda	Executive Officer	less than a year	Veri yok	Veri yok
Shinichiro Arikawa	Executive Officer	less than a year	Veri yok	Veri yok

3.2yrs

Ortalama Görev Süresi

Deneyimli Yönetim: 4551 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Goichi Matsuda	President	5.7yrs	Veri yok	0.065% ¥ 85.0m
Nobumasa Kondo	Executive Deputy President & Representative Director	less than a year	Veri yok	0.015% ¥ 19.2m
Mihoko Manabe	Director	less than a year	Veri yok	Veri yok
Takaharu Matsumura	Director	less than a year	Veri yok	Veri yok
Kenichi Fujita	Director	less than a year	Veri yok	Veri yok

0.7yrs

Ortalama Görev Süresi

56.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 4551 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 0.7 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Torii Pharmaceutical Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

No independent directors

Torii Pharmaceutical Co., Ltd., Annual General Meeting, Mar 27, 2024

Insufficient new directors

Recent updates

Third quarter 2024 earnings released: EPS: JP¥46.39 (vs JP¥45.62 in 3Q 2023)

Torii Pharmaceutical Co., Ltd. to Report Nine Months, 2025 Results on Oct 30, 2025

Price target decreased by 7.2% to JP¥4,035

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: EPS: JP¥47.78 (vs JP¥48.89 in 2Q 2023)

First half dividend of JP¥60.00 announced

Upcoming dividend of JP¥60.00 per share

No independent directors

First quarter 2024 earnings released: EPS: JP¥31.24 (vs JP¥10.25 loss in 1Q 2023)

Final dividend of JP¥60.00 announced

Full year 2023 earnings released: EPS: JP¥147 (vs JP¥140 in FY 2022)

Upcoming dividend of JP¥50.00 per share at 2.8% yield

Torii Pharmaceutical Co., Ltd. Announces Positive Top-Line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan

Third quarter 2023 earnings released: EPS: JP¥45.61 (vs JP¥35.98 in 3Q 2022)

Torii Pharmaceutical Co., Ltd., Annual General Meeting, Mar 27, 2024

Price target increased by 7.3% to JP¥3,685

Second quarter 2023 earnings released: EPS: JP¥48.89 (vs JP¥34.28 in 2Q 2022)

Upcoming dividend of JP¥50.00 per share at 1.3% yield

Insufficient new directors

Full year 2022 earnings released: EPS: JP¥140 (vs JP¥120 in FY 2021)

Price target decreased by 11% to JP¥3,100

Full year 2022 earnings released: EPS: JP¥140 (vs JP¥120 in FY 2021)

Upcoming dividend of JP¥24.00 per share

Third quarter 2022 earnings released: EPS: JP¥35.98 (vs JP¥35.39 in 3Q 2021)

Torii Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on Feb 10, 2023

Torii Pharmaceutical Co., Ltd. Announces Start of Phase 3 Trial of VP-102 for the Treatment of Molluscum Contagiosum

Second quarter 2022 earnings released: EPS: JP¥34.27 (vs JP¥28.76 in 2Q 2021)

Upcoming dividend of JP¥24.00 per share

First quarter 2022 earnings released: EPS: JP¥31.40 (vs JP¥15.52 in 1Q 2021)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Upcoming dividend of JP¥24.00 per share

Third quarter 2021 earnings released: EPS JP¥35.38 (vs JP¥25.21 in 3Q 2020)

Second quarter 2021 earnings released: EPS JP¥28.76 (vs JP¥33.41 in 2Q 2020)

Price target decreased to JP¥2,500

Upcoming dividend of JP¥24.00 per share

Torii Pharmaceutical Co., Ltd. Plans to Launch of CORECTIM Ointment 0.25% in Japan

First quarter 2021 earnings released: EPS JP¥15.52 (vs JP¥30.71 in 1Q 2020)

Full year 2020 earnings released: EPS JP¥124 (vs JP¥975 in FY 2019)

New 90-day low: JP¥2,997

New 90-day low: JP¥3,130

Full year 2020 earnings released: EPS JP¥124 (vs JP¥975 in FY 2019)

New 90-day high: JP¥3,325

Price target raised to JP¥3,600

Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. Receives Manufacturing and Marketing Approval of Enaroy Tablets 2 Mg4 Mg

Iwaki Seiyaku Co., Ltd. entered into an agreement to acquire Sakura Plant from Torii Pharmaceutical Co., Ltd. (TSE:4551) for ¥1.1 billion.

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş